Literature DB >> 18040689

Suppression of human macrophage interleukin-6 by a nonpsychoactive cannabinoid acid.

Jennifer Parker1, Francisco Atez, Ronald G Rossetti, Ann Skulas, Rakesh Patel, Robert B Zurier.   

Abstract

Interleukin-6 (IL-6) is a multifunctional cytokine which contributes to inflammation and tissue injury in several diseases. Thus, inhibition of IL-6 production may be a useful strategy for treatment of patients with diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). A synthetic nonpsychoactive cannabinoid, ajulemic acid (AjA), prevents joint damage in experimental arthritis. Results of experiments presented here indicate that addition of AjA (3-30 microM) to human monocyte derived macrophages in vitro reduces steady state levels of IL-6 mRNA and the subsequent secretion of IL-6 from LPS stimulated cells. Although AjA binds to and activates PPARgamma, its anti IL-6 effects are PPARgamma independent. These studies provide evidence to support the view that AjA may prove to be an effective, safe antiinflammatory agent.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18040689     DOI: 10.1007/s00296-007-0489-0

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  33 in total

Review 1.  PPARgamma ligands as modulators of inflammatory and catabolic responses in arthritis. An overview.

Authors:  Hassan Fahmi; Jean-Pierre Pelletier; Johanne Martel-Pelletier
Journal:  J Rheumatol       Date:  2002-01       Impact factor: 4.666

2.  Role of interleukin 6 (IL-6)/IL-6R-induced signal tranducers and activators of transcription and mitogen-activated protein kinase/extracellular.

Authors:  Florence Legendre; Patrick Bogdanowicz; Karim Boumediene; Jean-Pierre Pujol
Journal:  J Rheumatol       Date:  2005-07       Impact factor: 4.666

Review 3.  Regulatory mechanisms operative in osteoclasts.

Authors:  Sakamuri V Reddy
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2004       Impact factor: 1.807

4.  Inhibition of T cell apoptosis in the rheumatoid synovium.

Authors:  M Salmon; D Scheel-Toellner; A P Huissoon; D Pilling; N Shamsadeen; H Hyde; A D D'Angeac; P A Bacon; P Emery; A N Akbar
Journal:  J Clin Invest       Date:  1997-02-01       Impact factor: 14.808

Review 5.  The role of the synovial fibroblast in rheumatoid arthritis: cartilage destruction and the regulation of matrix metalloproteinases.

Authors:  Aryeh M Abeles; Michael H Pillinger
Journal:  Bull NYU Hosp Jt Dis       Date:  2006

6.  Activation and binding of peroxisome proliferator-activated receptor gamma by synthetic cannabinoid ajulemic acid.

Authors:  Jilin Liu; Hui Li; Sumner H Burstein; Robert B Zurier; J Don Chen
Journal:  Mol Pharmacol       Date:  2003-05       Impact factor: 4.436

7.  Interleukin 6 plays a key role in the development of antigen-induced arthritis.

Authors:  S Ohshima; Y Saeki; T Mima; M Sasai; K Nishioka; S Nomura; M Kopf; Y Katada; T Tanaka; M Suemura; T Kishimoto
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

8.  Suppression of human monocyte interleukin-1beta production by ajulemic acid, a nonpsychoactive cannabinoid.

Authors:  Robert B Zurier; Ronald G Rossetti; Sumner H Burstein; Bonnie Bidinger
Journal:  Biochem Pharmacol       Date:  2003-02-15       Impact factor: 5.858

9.  Synthetic nonpsychotropic cannabinoids with potent antiinflammatory, analgesic, and leukocyte antiadhesion activities.

Authors:  S H Burstein; C A Audette; A Breuer; W A Devane; S Colodner; S A Doyle; R Mechoulam
Journal:  J Med Chem       Date:  1992-08-21       Impact factor: 7.446

10.  T-cell contact-dependent regulation of CC and CXC chemokine production in monocytes through differential involvement of NFkappaB: implications for rheumatoid arthritis.

Authors:  Jonathan T Beech; Evangelos Andreakos; Cathleen J Ciesielski; Patricia Green; Brian M J Foxwell; Fionula M Brennan
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

View more
  12 in total

Review 1.  The Endocannabinoid System and Heart Disease: The Role of Cannabinoid Receptor Type 2.

Authors:  Makenzie L Fulmer; Douglas P Thewke
Journal:  Cardiovasc Hematol Disord Drug Targets       Date:  2018

2.  Cannabinoid Reduces Inflammatory Cytokines, Tumor Necrosis Factor-α, and Type I Interferons in Dermatomyositis In Vitro.

Authors:  Elizabeth S Robinson; Paul Alves; Muhammad M Bashir; Majid Zeidi; Rui Feng; Victoria P Werth
Journal:  J Invest Dermatol       Date:  2017-06-23       Impact factor: 8.551

3.  Allostatic load and the cannabinoid system: implications for the treatment of physiological abnormalities in post-traumatic stress disorder (PTSD).

Authors:  James B Lohr; Hang Chang; Michelle Sexton; Barton W Palmer
Journal:  CNS Spectr       Date:  2019-07-15       Impact factor: 3.790

Review 4.  Cannabinoids as novel anti-inflammatory drugs.

Authors:  Prakash Nagarkatti; Rupal Pandey; Sadiye Amcaoglu Rieder; Venkatesh L Hegde; Mitzi Nagarkatti
Journal:  Future Med Chem       Date:  2009-10       Impact factor: 3.808

5.  Ajulemic acid, a synthetic cannabinoid, increases formation of the endogenous proresolving and anti-inflammatory eicosanoid, lipoxin A4.

Authors:  Robert B Zurier; Yee-Ping Sun; Kerri L George; Judith A Stebulis; Ronald G Rossetti; Ann Skulas; Erica Judge; Charles N Serhan
Journal:  FASEB J       Date:  2009-01-05       Impact factor: 5.191

Review 6.  Cannabinoids, endocannabinoids, and related analogs in inflammation.

Authors:  Sumner H Burstein; Robert B Zurier
Journal:  AAPS J       Date:  2009-02-06       Impact factor: 4.009

Review 7.  Interaction between Cannabinoid System and Toll-Like Receptors Controls Inflammation.

Authors:  Kathleen L McCoy
Journal:  Mediators Inflamm       Date:  2016-08-11       Impact factor: 4.711

Review 8.  Relevance of Peroxisome Proliferator Activated Receptors in Multitarget Paradigm Associated with the Endocannabinoid System.

Authors:  Ana Lago-Fernandez; Sara Zarzo-Arias; Nadine Jagerovic; Paula Morales
Journal:  Int J Mol Sci       Date:  2021-01-20       Impact factor: 5.923

Review 9.  An update on PPAR activation by cannabinoids.

Authors:  Saoirse Elizabeth O'Sullivan
Journal:  Br J Pharmacol       Date:  2016-05-19       Impact factor: 8.739

10.  Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis.

Authors:  Robert Spiera; Laura Hummers; Lorinda Chung; Tracy M Frech; Robyn Domsic; Vivien Hsu; Daniel E Furst; Jessica Gordon; Maureen Mayes; Robert Simms; Robert Lafyatis; Viktor Martyanov; Tammara Wood; Michael L Whitfield; Scott Constantine; Elizabeth Lee; Nancy Dgetluck; Barbara White
Journal:  Arthritis Rheumatol       Date:  2020-07-17       Impact factor: 10.995

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.